In the Claims:

Please amend claims 1 and 5 as below:

1. (currently amended) A pharmaceutical formulation comprising a cytoprotection effective dose of a compound, comprising: a polycyclic compound having the structure below:

wherein the alkyl group R in the alkyl ether group OR includes any of a long chain saturated alkyl, a long chain unsaturated alkyl, or a cycloalkyl group [optionally having a four ring estrogen structure having a first end and a second end wherein a phenol group is located at the first end and a D carbon ring is located at the second end, the D carbon ring having an alkyl ether functional group on carbon 17 thereof, the alkyl portion of which is any of a long chain saturated alkyl, a long chain unsaturated alkyl, or a cycloalkyl group].

2-4. (cancelled)

- 5. (currently amended) A pharmaceutical formulation <u>according</u> to claim 1, wherein the alkyl ether functional group is in an orientation selected from the group consisting of an alpha or beta isomeric orientation on the carbon.
- 6. (previously presented) A pharmaceutical formulation according to claim 1, wherein the alkyl group in the alkyl ether functional group is characterized by the formula of $C_nH_{(2n+1)}$ wherein n is at least 3 and less than 20.
- 7. (previously presented) A pharmaceutical formulation according to claim 1, comprising: a 17-butoxyestra 1,3,5(10) triene-3-ol.
- 8. (previously presented) A pharmaceutical formulation according to claim 1, comprising: a 17-hexyloxyestra-1, 3,5(10)-triene-3-ol.
- 9. (previously presented) A pharmaceutical formulation according to claim 1, comprising: a 17- octyloxyestra-1, 3,5(10)-triene-3-ol.

10-11. (**cancelled**)